As of May 28, 2025, Arcturus Therapeutics Holdings Inc (ARCT) reports a Net Margin of -53.14%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Arcturus Therapeutics Holdings Inc's Net Margin
Over recent years, Arcturus Therapeutics Holdings Inc's Net Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2024-12-31 | -53.14% |
| 2023-12-31 | -17.49% |
| 2022-12-31 | 4.51% |
| 2021-12-31 | -1642.74% |
| 2020-12-31 | -758.95% |
This gradual decrease highlights how Arcturus Therapeutics Holdings Inc manages its overall profitability and cost control over time.
Comparing Arcturus Therapeutics Holdings Inc's Net Margin to Peers
To better understand Arcturus Therapeutics Holdings Inc's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Arcturus Therapeutics Holdings Inc (ARCT) | -53.14% |
| Inhibrx Inc (INBX) | 843786.00% |
| Regeneron Pharmaceuticals Inc (REGN) | 31.07% |
| Amgen Inc (AMGN) | 12.24% |
| Dynavax Technologies Corp (DVAX) | 9.85% |
| Abbvie Inc (ABBV) | 7.59% |
Compared to its competitors, Arcturus Therapeutics Holdings Inc's Net Margin is about average compared to peers, reflecting typical industry profitability.